RxDoctor Payments Data

Cyril Anyadike, MD

Gastroenterology · Los Angeles, CANPI 1952322984

Payments from drug & device makers

$15,443in general payments, 2019–2025

Across 661 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Pfizer$4K
  • AbbVie$4K
  • Gilead$858
  • Madrigal Pharmaceuticals$778
  • Redhill Biopharma Inc.$535
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$11,92799%
  • Education$130%
  • Gifts$530%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,443 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$47,527
Medicare patients
211
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin38$111,545
LinzessLinaclotide98$91,470
CreonLipase/Protease/Amylase16$25,985
VemlidyTenofovir Alafenamide17$23,133
TrulancePlecanatide28$22,212
Mesalamine17$19,427
TaliciaOmeprazole/Amoxicill/Rifabutin13$10,403
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl421$6,292
Mesalamine ErMesalamine17$6,115
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,638
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C31$4,293
Dexlansoprazole DrDexlansoprazole14$4,220
Tenofovir Disoproxil Fumarate11$1,830
Famotidine172$1,682
Pantoprazole Sodium188$1,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$4,129$138,05097 claims
AbbVieLinzess, Creon$3,649$117,455114 claims
GileadVemlidy$858$23,13317 claims
Redhill Biopharma Inc.Talicia$535$10,40313 claims
Braintree Laboratories, Inc.Sutab, Suflave$101$6,10541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →